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ABSTRACT
Rationale The molecular mechanisms underlying the
muscle atrophy of intensive care unit-acquired weakness
(ICUAW) are poorly understood. We hypothesised that
increased circulating and muscle growth and
differentiation factor-15 (GDF-15) causes atrophy in
ICUAW by changing expression of key microRNAs.
Objectives To investigate GDF-15 and microRNA
expression in patients with ICUAW and to elucidate
possible mechanisms by which they cause muscle
atrophy in vivo and in vitro.
Methods In an observational study, 20 patients with
ICUAW and seven elective surgical patients (controls)
underwent rectus femoris muscle biopsy and blood
sampling. mRNA and microRNA expression of target
genes were examined in muscle specimens and GDF-15
protein concentration quantiﬁed in plasma. The effects
of GDF-15 on C2C12 myotubes in vitro were examined.
Measurements and main results Compared with
controls, GDF-15 protein was elevated in plasma
(median 7239 vs 2454 pg/mL, p=0.001) and GDF-15
mRNA in the muscle (median twofold increase p=0.006)
of patients with ICUAW. The expression of microRNAs
involved in muscle homeostasis was signiﬁcantly lower in
the muscle of patients with ICUAW. GDF-15 treatment
of C2C12 myotubes signiﬁcantly elevated expression of
muscle atrophy-related genes and down-regulated the
expression of muscle microRNAs. miR-181a suppressed
transforming growth factor-β (TGF-β) responses in
C2C12 cells, suggesting increased sensitivity to TGF-β in
ICUAW muscle. Consistent with this suggestion, nuclear
phospho-small mothers against decapentaplegic (SMAD)
2/3 was increased in ICUAW muscle.
Conclusions GDF-15 may increase sensitivity to TGF-β
signalling by suppressing the expression of muscle
microRNAs, thereby promoting muscle atrophy in
ICUAW. This study identiﬁes both GDF-15 and
associated microRNA as potential therapeutic targets.
INTRODUCTION
Intensive care unit-acquired weakness (ICUAW) is a
potentially devastating complication of critical
illness. Up to 50% of patients who have been critic-
ally unwell for more than 1 week experience sig-
niﬁcant muscle wasting and weakness,1 associated
with signiﬁcant mortality, delayed weaning from
mechanical ventilation, increased intensive care unit
(ICU) and hospital length of stay and long-term dis-
ability.2 Muscle homeostasis is disturbed by an
imbalance between protein synthesis and break-
down, resulting in net muscle loss.3 The molecular
mechanisms of ICUAW are not well understood,
but it is likely that the aetiology is multifactorial.2 4
There are currently no pharmacological treatments,
and few potential therapeutic targets have been
identiﬁed.
Growth and differentiation factor 15 (GDF-15),
a transforming growth factor-β (TGF-β) family
member, is a stress-induced cytokine.5 GDF-15 is
released from various tissues, including heart and
liver, in response to inﬂammation, oxidative stress
and hypoxia.5 6 GDF-15 was proapoptotic in
cancer cells6 and prevented hypertrophy of cardiac
myocytes in vitro7 and caused cachexia in murine
tumour models.8 We previously demonstrated that
prolonged elevation in circulating GDF-15 concen-
trations following high-risk cardiac surgery necessi-
tating ICU admission was associated with muscle
wasting and, in vitro, that GDF-15 caused myotube
atrophy.9
MicroRNAs are small non-coding RNA that
regulate the translation and stability of speciﬁc
mRNAs. In muscle, microRNAs modulate regener-
ation, differentiation and ﬁbre type.10 For example,
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Key messages
What is the key question?
▸ Based on our prior studies, we hypothesised
that growth and differentiation factor-15
(GDF-15), a transforming growth factor-β
(TGF-β) super-family member, would play a role
in causing muscle atrophy in intensive care
unit-acquired weakness (ICUAW).
What is the bottom line?
▸ Our data suggest that in critical illness,
associated muscle wasting may, in part, be
mediated by increased GDF-15 expression and
consequent down-regulation of muscle-speciﬁc
microRNA, which are known to control muscle
homeostasis.
Why read on?
▸ This article describes a novel molecular mechanism
that is potentially important in the pathogenesis of
ICUAW and a novel therapeutic target.
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miR-1 and miR-133a ﬁne-tune the balance between prolifer-
ation and differentiation. Inhibition of these microRNAs pre-
vented normal proliferation and differentiation of myoblasts.11
MiR-181a, although not restricted to muscle, was essential for
the regulation of muscle differentiation and recovery.12
MicroRNAs have multiple, speciﬁc mRNA targets, and altered
microRNA expression has been described in muscle diseases.10 13
MicroRNA expression can be controlled by inﬂammatory cyto-
kines and, in turn, microRNAs modulate inﬂammatory signal-
ling,14 including TGF-β pathways. For example, miR-1,
miR-133a, miR-181a and miR-499 interacted with TFG-β sig-
nalling pathways in several cell lines.15–17 TGF-β signalling via
small mothers against decapentaplegic (SMAD) protein phos-
phorylation is an essential pathway in muscle atrophy that can
be stimulated by various ligands, including myostatin (GDF-8)
and TGF-β1.18 In this observational study, we hypothesised that
GDF-15, both muscle and from the circulation, mediates
ICUAW-associated muscle atrophy through regulation of
microRNA expression.
METHODS
Full method description can be found in the online repository.
A brief description is given here.
Clinical setting, patients, controls and study design
This study was carried out in a specialist cardiothoracic ICU.
Patients were admitted to ICU, either following cardiothoracic
surgery, from the general wards with complex and often chronic
cardiorespiratory diseases, or from other centres for extracor-
poreal membrane oxygenation for severe acute respiratory
failure. The principal inclusion criterion for this study was a
diagnosis of ICUAW, made in accordance with standard diagnos-
tic criteria;19 where patients were alert and cooperative, this
included Medical Research Council (MRC) strength score evalu-
ation (n=8), but in the majority their level of consciousness pre-
cluded MRC scoring. In these cases, in line with Stevens’
criteria, patients were required to have visible evidence of
muscle wasting and functional evidence of muscle weakness,
where other causes of muscle wasting and weakness were
excluded. All adults admitted to our ICU for more than 1 week
were screened. Exclusion criteria included previous neuromus-
cular disease, resulting in signiﬁcant wasting or weakness, malig-
nancy or contraindication to biopsy. Control participants were
elective high-risk cardiothoracic surgery patients, with MRC
scores 60/60 preoperatively, in whom a biopsy was taken at the
start of surgery. This population was chosen to control for the
complex comorbidities of patients with ICUAW. Written
informed consent was obtained from study subjects or assent
from the next of kin where the patient lacked capacity.
Mid-thigh muscle layer thickness
Muscle layer thickness (MLT) of the mid-thigh was measured as
previously described.20
Muscle biopsy and blood processing
Rectus femoris biopsy samples were ﬂash frozen or cork
mounted and frozen. Plasma was taken at the same time as
muscle biopsies and was separated from blood collected into
EDTA sample tubes centrifuged at 1500 g (3500 rpm) for
10 min. Plasma and muscle samples were stored at −80°C.
Muscle biopsy specimens were available for mRNA quantiﬁca-
tion for all seven controls and 20 patients; however, only 19
patients had sufﬁcient RNA to allow quantiﬁcation of
microRNAs; microRNAs were measured in all seven controls.
Adequate histology specimens were available for 4/7 controls
and 7/20 patients. Plasma GDF-15 was quantiﬁed by ELISA
(R&D systems, Abingdon, UK). RNA extraction and quantiﬁca-
tion, histology and immunoﬂuorescence were carried out using
validated techniques described in the online repository.
Table 1 Basic baseline demographic data, comorbidities and ICU
data (where applicable) for patients with ICUAW and controls
Controls
(n=7) Patients (n=20)
p Value
(MW/χ2)
Demographics
Age (years) 69 (63–74) 64 (51–78) 0.39
Sex (m/f) 7/0 15/5 0.14
BMI (baseline) (kg/m2) 24 (22–29) 27.8 (26.0–30.8) 0.21
MLT* (cm) 2.9 (2.0–3.3) 1.7 (1.4–2.5) 0.08
Comorbidities (n)
IHD 4 of 7 8 of 20 0.42
Other cardiac disease 6 of 7 6 of 20 0.01
Respiratory 0 of 7 6 of 20 0.10
COPD 0 of 7 2 of 20
Diabetes 1 of 7 4 of 20 0.73
Statin use 4 of 7 6 of 20 0.20
Type on cardiac surgery (n)
CABG 1
Valve surgery 2
Mixed 4
Reason for ICU admission (n)
Postcardiac surgery 8
Cardiac 3
Respiratory 9
Pneumonia 2
COPD 2
ARDS/ECMO 3
Other respiratory 2
ICU data
MRC score at diagnosis† 36 (34–40)
Day on ICU of biopsy (days) 20 (15–29)
SOFA score at time of biopsy 11 (8–14)
Total ICU LOS (days) 42 (23–51)
Awake at biopsy (n) 6
Fed at time of biopsy 6
NMB (n) 11
Corticosteroids (n) 12
Sepsis (n) 20
Mean CRP (mg/L)‡ 136 (103–194)
Mean pO2 (kPa)‡ 12.68
(12.12–14.41)
Mean CO2 (kPa)‡ 5.7 (5.31–6.09)
Mean pH‡ 7.41 (7.40–7.44)
Mean blood glucose (mg/dL)‡ 7.6 (7.1–8.0)
Mean cumulative insulin
dose (Units)‡
456 (345–894)
Died (1-year mortality) 8
Data presented as median (IQR) or number (n).
*n=5 for controls and n=13 for patients.
†n=8 (six on the day of biopsy, two in the preceding 48 h).
‡During ICU stay up to the point of biopsy.
ARDS, acute respiratory distress syndrome; BMI, body mass index; CABG, coronary
artery bypass graft; CRP, C-reactive protein; ECMO, extracorporeal membrane
oxygenation; ICU, intensive care unit; ICUAW, intensive care unit-acquired weakness;
IHD, ischaemic heart disease; LOS, length of stay; MLT, muscle layer thickness; MRC,
Medical Research Council; NMB, neuromuscular blockers; SOFA, Sequential Organ
Failure Assessment.
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C2C12 cell culture, transfection of luciferases and overexpres-
sion of mir-181a are described in the online repository.
Data and statistical analysis
Clinical data are described as median with IQR as the control
group only consists of seven individuals. Mann–Whitney tests
were used for between-group comparisons. χ2 tests were used to
compare absolute categorical demographic data between patient
and control groups. In vitro data are described as mean±SD
and analysed by Student t test. Pearson’s test for signiﬁcant cor-
relation was used and the resulting p values were Bonferroni
corrected for multiple comparisons where appropriate.
Statistical analysis and ﬁgure construction was carried out using
GraphPad PRISM V.6 (GraphPad Software, California, USA).
RESULTS
Patients and controls
In total, 20 of 29 patients meeting the inclusion criteria were
recruited (ﬁgure E1). Seven high-risk cardiothoracic patients were
recruited as controls (median EuroSCORE 9 (range 7–14)).
Demographic data, comorbidities, reason for ICU admission and
clinical data from ICU stay are shown in table 1. Patients and con-
trols were well matched for age and baseline body mass index;
however, the controls were all men. Owing to technical factors,
including oedema, adequate ultrasound images were obtained in
only ﬁve controls and 13 patients; as expected in this small sample
mid-thigh MLT tended to be lower in patients than controls (1.7
(1.4–2.5) cm vs 2.9 (2.0–3.3) cm, respectively; p=0.079).
Histology
Mean muscle ﬁbre diameter for each individual was calculated
from a median of 74 ﬁbres (range 33–105 ﬁbres/subject) depend-
ing on the size of the biopsy sample. Median mean ﬁbre diameter
was 56.4 (49.5–62.2) mm in controls and signiﬁcantly lower in
patients, 47.5 (41.9–51.6) mm (p=0.042). The frequency distri-
bution of ﬁbre size also conﬁrmed that patients had smaller ﬁbres
as a percentage of total ﬁbres measured (ﬁgure 1). Both MHC1
and MHC2a mRNA expression were signiﬁcantly reduced in
Figure 1 Muscle biopsy specimens
from the rectus femoris of ICUAW
(n=7) and controls (n=4). H&E staining
of muscle biopsies from control
subjects (A) and patients (B) at 10×
magniﬁcation. Immunostaining of the
same control (C) and patient (D) for
different muscle ﬁbre types. Samples
are representative of their respective
groups. Blue, MHC 1; green, MHC 2a;
red, laminin: type 2× ﬁbres do not
stain and can be seen as black ﬁbres
(10× magniﬁcation). (E) Mean ﬁbre
diameter of patients and controls.
(F) Percentage distribution of all ﬁbres
measured (33–107 measured per
subject). (G) Mean ﬁbre type
proportion of different MHCs 1, 2a, 2x
and dual staining 1/2a ﬁbres. (H)
mRNA expression for different MHCs.
Controls n=7, patients n=20; data
presented as median and error bars
represent IQR, *p<0.05, **p<0.01,
***p<0.001 Mann–Whitney. ICUAW,
intensive care unit-acquired weakness;
MHC, myosin heavy chain.
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patients compared with controls (ﬁgure 1), whereas, MHC2x
mRNA expression was not different. Immunoﬂuorescent staining
of specimens conﬁrmed ﬁbre atrophy; mean type 1 ﬁbre diameter
was 15% smaller in patients than controls (p<0.001 t test) and
type 2a ﬁbres were 24% smaller (p<0.001 t test). This analysis
also showed a non-signiﬁcant shift in ﬁbre proportion towards
MHC2a ﬁbres; median proportions of MHC1 and MHC2a
ﬁbres were 44% (35–61) and 33% (28–38), respectively, in con-
trols and 24% (21–39) and 45% (18–72) in patients (p=0.109
for type 1 ﬁbres and 0.715 for type 2a—Mann–Whitney,
ﬁgure 1).
GDF-15 was elevated in plasma and muscle of patients
Median plasma GDF-15 concentration in controls was 2454 pg/mL
(600–3118) and 7239 pg/mL (5613–13 295) in patients (ﬁgure 2,
p=0.001). At the time of biopsy, plasma GDF-15 in the patients
correlated with their Sequential Organ Failure Assessment (SOFA)
score, a marker of critical illness severity21 (r=0.64, p=0.002).
Rectus femoris muscle mRNA expression of GDF-15 was
higher in patients than controls (median 2.03-fold (1.2–3.1)
higher than controls, p=0.006: ﬁgure 2).
Neither myostatin, insulin-like growth factor-1 (IGF-1) or
Muscle Ring Finger-1 (MuRF-1) mRNA expression were signiﬁ-
cantly different between patients and controls (online repository
ﬁgure E2). Expression of atrogin was elevated signiﬁcantly in
patients (median 3.42-fold (1.7–7.9) higher than controls,
p=0.003, ﬁgure 3).
MicroRNA expression proﬁle
The expression of three muscle-speciﬁc microRNAs (myomiRs),
miR-1, miR-133a and miR-499, were signiﬁcantly reduced
in the rectus femoris muscle of patients compared with
controls. Median patient myomiR expression as percentage of
control: miR-1 39% (22%–69%), p=0.003; miR-133a 38%
(28%–47%), p<0.001; miR-49 927% (17%–41%) p=0.002.
MiR-206, another myomiR, was not different between the two
groups. Median miR-181a expression in patients was 56%
(42%–77%) of control values, p=0.009 (ﬁgure 4). Log
(GDF-15 mRNA) showed a signiﬁcant negative correlation with
log microRNA expression of miR-1, miR-133a, miR-181a and
miR-499, but not miR-206. Log (plasma GDF-15) showed
similar signiﬁcant correlations with the myomiRs but not with
miR-181a (ﬁgure 4).
Increased activity of the TGF-β signalling pathway
in ICUAW muscle
Cysteine-rich, angiogenic inducer-61 (CYR61) mRNA expression
in ICUAW muscle, a downstream marker of TGF-β signalling,22
was signiﬁcantly increased (median 11.18-fold (5.32–15.75)
higher than controls p<0.001, ﬁgure 3).
Binding of TGF-β family ligands (eg, TGF-β1 or myostatin) to
their receptors causes phosphorylation of SMAD2/3, which in turn
become localised to the nucleus and act as transcription factors for
TGF-β-responsive genes.23 As such, nuclear positivity for phos-
phorylated SMAD2/3 reﬂects TGF-β family signalling.
Immunostained muscle sections demonstrated a higher percentage
of nuclei staining positive for phosphorylated SMAD2/3 in patients
(median 92% (87%–95%)) vs controls (79% (78%–86%)),
p=0.042 (ﬁgure 5).
Figure 2 Growth and differentiation factor-15 (GDF-15) in patients
with intensive care unit-acquired weakness patients (n=20) and
controls (n=7) measured in plasma (A) and rectus femoris muscle
biopsy mRNA expression (B). Dotted line in (A) represents 1200 pg/mL
—the upper limit of normal plasma GDF-15. Data shown as median
and IQR; **p<0.01, ***p<0.001—Mann–Whitney. Correlation of
plasma GDF-15 with Sequential Organ Failure Assessment (SOFA) score
at the time of sampling (C), r=Pearson’s r value for correlation.
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GDF-15 effects on myotubes
To determine whether GDF-15 could induce similar changes in
gene expression, C2C12 myotubes were treated for 4 days with
GDF-15 (50 ng/mL). MuRF-1 and atrogin mRNA expression
were signiﬁcantly elevated; however, CYR61 did not change
(ﬁgure 6).
Consistent with the in vivo data, miR-1, miR-133a and
miR-181a were reduced and miR-206 was unaltered. However,
unlike in vivo, miR-499 was unchanged (ﬁgure 6).
MiR-181a overexpression reduces TGF-β signalling
Treatment of C2C12 myoblasts with TGF-β1 (2.5 ng/mL)
caused a 24-fold induction of CAGA-12-driven luciferase activ-
ity. Overexpression of miR-181a in cultured myoblasts reduced
this response by 45% (ﬁgure 6).
DISCUSSION
The main ﬁndings of this study are that both circulating GDF-15
and muscle GDF-15 mRNA expression were elevated in patients
with ICUAW compared with controls (ﬁgure 2). Moreover expres-
sion of microRNAs known to be important in muscle homeostasis
and the modulation of TGF-β response were suppressed in
ICUAW muscle (ﬁgure 4). Lastly GDF-15 can drive the reduction
in these microRNAs in differentiated myotubes in vitro and that
suppression of miR-181a may increase tissue sensitivity to TGF-β
signalling (ﬁgure 6). Taken together with the evidence of increased
TGF-β signalling in ICUAW muscle (ﬁgure 5), these data support
the hypothesis that GDF-15 may be a mediator of acute muscle
wasting in the critically ill and demonstrate that this activity may
result from down-regulation of microRNAs, potentially leading to
increased sensitivity to TGF-β signalling (ﬁgure 7).
The increase in circulating GDF-15 in patients with ICUAW,
which is consistent with our previous study,9 is likely to be a
result of critical illness because factors thought to contribute to
ICUAW, including hyperglycaemia, inﬂammation and oxidative
stress,2 4 stimulate GDF-15 expression in other tissues6 24 and,
therefore, may drive the observed increase in GDF-15 expres-
sion in ICUAW muscle. The concept that circulating GDF-15
reﬂects illness severity is supported by our observation that
patients’ plasma GDF-15 correlated with their SOFA score
(ﬁgure 2) and prior observations that elevated GDF-15 in
patients with acute respiratory distress syndrome predicted poor
outcome.25
GDF-15, like other TGF-β family members, probably acts in
both a paracrine and endocrine manner,6 and we have previ-
ously shown that GDF-15 can cause myotube atrophy in vitro;9
it is, therefore, feasible that elevation of both plasma and
muscle GDF-15 promote ICUAW. Consistent with the concept
that GDF-15 promotes myotube atrophy, GDF-15 treatment of
cultured myotubes increased MuRF-1 and atrogin mRNA
expression (ﬁgure 6). A direct role for GDF-15 in wasting is
also consistent with the observation that GDF-15 prevented
hypertrophy of cardiac myocytes;7 while these effects may be
protective in cardiac muscle, they could promote pathological
atrophy in skeletal muscle. While the concentration of GDF-15
used in vitro is higher than that measured in vivo, it is not pos-
sible to compare the relative sensitivity of the two different
systems to endogenous or recombinant protein.
We showed that muscle of patients with ICUAW showed fea-
tures consistent with increased TGF-β signalling, speciﬁcally
increased expression of Cyr-61 and in a subgroup of patients an
increased proportion of nuclei containing phosphorylated
SMAD2/3 (ﬁgure 5). By contrast, in vitro studies in myoblasts
or myotubes stimulated by GDF-15 did not show increased
SMAD-dependent luciferase reporter gene activity
(CAGA12-luc; data not shown) or increased Cyr-61 expression
(ﬁgure 6), suggesting that these are not direct effects of
GDF-15. In ICUAW muscle, we observed suppression of a
number of microRNAs that inhibit various components of the
TGF-β signalling pathway and, therefore, could account for the
increase in Cyr-61 and nuclear p-SMAD2/3. Furthermore,
GDF-15 treatment of myotubes suppressed expression of the
same microRNAs, and GDF-15 mRNA expression in muscle
and plasma of patients with ICUAW was inversely correlated
with expression of muscle microRNAs (ﬁgure 4).
MyomiRs are essential for normal muscle homeostasis;10
therefore, suppression of these microRNAs by GDF-15 may
contribute to muscle wasting in patients. Consistent with a pro-
tective role for these microRNAs is their ability to down-
regulate components of TGF-β signalling pathways. For
example, miR-1 and miR-499 (both suppressed in our patient
cohort) inhibited myostatin signalling. MiR-1 increases follista-
tin expression by suppressing histone deacetylase 4 (HDAC4, an
inhibitor of follistatin expression) and thereby inactivates
circulating myostatin,16 miR-499 binds to the myostatin
30-untranslated region26 and both are predicted to target the
Figure 3 Rectus femoris muscle mRNA expression of different mRNA in patients with intensive care unit-acquired weakness (n=20) and controls
(n=7) for atrogin and CYR61 (cytosine rich protein 61 (CYR61). Data presented as median and error bars represent IQR; **p<0.01, ***p<0.001
Mann–Whitney.
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activin IIB receptor.16 27 HDAC4 also suppresses the expression
of muscle-speciﬁc genes17 and the expression of DACH2
(daschund family transcription factor 2), an indirect inhibitor of
MuRF1 and atrogin expression.28 Thus, the reduction in miR-1
may also contribute to the reduction in MHC expression and
the increase in atrogin expression we observed. MiR-133a, also
suppressed in these patients,17 targeted TGF-β receptor type 2
and TGF-β129 to down-regulate TGF-β signalling. MiR-181a,
also suppressed in our patients, promoted muscle recovery fol-
lowing injury12 and decreased cell sensitivity to TGF-β
Figure 4 Rectus femoris muscle microRNA expression in patients with intensive care unit-acquired weakness (n=19) and controls (n=7).
Table shows correlation of log (miR expression) with log (plasma growth and differentiation factor-15 (GDF-15)) and log (GDF-15 mRNA expression)
Pearson’s r values and p values (Bonferroni corrected for multiple testing) are listed. Data presented as median and error bars represent IQR;
**p<0.01, ***p<0.001, Mann–Whitney.
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signalling.15 Furthermore, we have demonstrated functional sup-
pression of TGF-β signalling in response to overexpression of
miR-181a in myoblasts (ﬁgure 6). Combining all of the targets
(predicted by at least four databases in miRwalk,30 a microRNA
target predicting tool) of the suppressed microRNAs in our
patients with ICUAW in a pathway analysis using DAVID31
(a functional annotation tool for understanding the potential
relationships and effects of lists of genes), highlights the TGF-β
signalling pathway as one of the major pathways likely to be
regulated. Indeed, the TGF-β pathway was the third most
statistically signiﬁcant pathway identiﬁed (p=0.005 at 2.2-fold
enrichment, table E1).
We, therefore, propose that the elevation of GDF-15 in
patients with ICUAW suppresses these microRNAs and thereby
sensitises muscle to TGF-β signalling (ﬁgure 7). It is possible
that GDF-15 sensitisation of muscle to TGF-β signalling is not
unique to ICUAW. Down-regulation of muscle microRNAs is
consistent with changes we have seen in COPD-associated
muscle dysfunction13 and that others have reported in inﬂam-
matory myopathies.14
Figure 5 Phosphorylated small mothers against decapentaplegic 2/3 (p-SMAD 2/3) nuclear staining of muscle specimens for patients and controls.
Images show control (left) and patient (right) 20× magniﬁcation muscle sections stained for p-SMAD2/3 localisation. Blue, 40,6-diamidino-2-phenylindole
nuclear; red, laminin; green, p-SMAD2/3. Lower images show p-SMAD2/3 ﬂuorescence only of the same ﬁeld of view, samples are representative of their
respective groups. Graph shows percentage of pSMAD2/3-positive nuclei for controls (n=4) and patients (n=7). Data are presented as median and IQR,
p=0.042, Mann–Whitney.
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Critique of the method
This study analysed a small patient population in a specialist car-
diothoracic ICU. While this approach reduces the heterogeneity of
participants, caution should be exercised in generalising our data
to broader ICU populations, particularly given the importance of
GDF-15 in cardiovascular disease.5 Only 8/20 patients were able
to complete the MRC score for diagnosis of ICUAW; however, all
patients were found to have deﬁnite evidence of visible muscle
wasting and functional muscle weakness, and within the criteria
set out by Stevens et al,19 the diagnosis was made by the clinical
team. Unfortunately, it was not possible to assess accurately the
cross-sectional area of the quadriceps muscle in these patients and
controls because either the muscle was too large for a single US
image or poor image quality in the patients due to oedema.
Therefore, the MLTwas used. Electromyography or nerve conduc-
tion studies were not undertaken in our patients. Neuropathy,
usually axonal, is a recognised feature in ICUAW2 and we cannot
exclude neuropathy as an aetiological factor in the molecular
changes observed in our study.
Instead of healthy controls, our control population was delib-
erately selected to match the baseline medical comorbidities of
this ICU’s patient population, thus allowing the effect of a pro-
longed critical illness on muscle to be examined. We could have
chosen a different control group such as patients earlier in their
ICU stay prior to the clinical development of muscle wasting;
however, we opted not to because molecular changes likely
precede clinically overt ICUAW3 and such patients with similar
levels of illness at an early stage of their ICU stay would already
be expected to exhibit molecular changes within their muscle
that cause ICUAW.
ICUAW occurs as a result of multiple pathological stimuli
causing a net breakdown in muscle protein. Therefore, we
might expect myostatin mRNA to be increased and IGF-1
mRNA to be reduced. However, in our patients with ICUAW,
neither changed signiﬁcantly (ﬁgure E2). It has recently been
shown that after an initial period of reduced muscle protein syn-
thesis a longer phase of increased catabolism predominates.3
Our group has previously found increased IGF-1 mRNA in
COPD-related muscle wasting,13 but other groups have found
decreased IGF-1 mRNA in human and animal muscle in
response to local infection and injury.32 33 Our patients had
been critically ill for a median of 20 days, while the studies men-
tioned examined shorter terms. Consequently, it is important to
note that different factors may contribute to ICUAW as the
disease progresses, and although these patients remained critic-
ally unwell (with elevated SOFA scores), this time point may not
reﬂect mechanisms that occurred early in the muscle insult of
critical illness.
With respect to muscle protein breakdown, atrogin mRNA
expression in muscle was elevated in the patient group (ﬁgure 3).
Proposed mediators of ICUAW,34 MuRF-1 and atrogin are muscle-
speciﬁc ligases that can be driven by myostatin.18 However,
neither MuRF-1 nor myostatin mRNA was elevated in the
patient’s muscle (ﬁgure E2). Human studies of short term of
immobilisation and acute illness35 have shown increased MuRF-1,
but this rise was lost in the longer term,35 36 and both human and
animal data concerning myostatin are inconsistent.34 36
A potential confounding factor in this study was the differ-
ing feeding status of patients and controls. All of our controls
were fasted at the time of biopsy, for surgery. However, it was
Figure 6 Effects of growth and
differentiation factor-15 (GDF-15) or
vehicle control on differentiated C2C12
myotubes. Day 8 differentiated C2C12
myotubes were treated with GDF-15
(50 ng/mL) or vehicle control (0.1%
bovine serum albumin with 20 mM
HCl) for 4 days, differential mRNA (A)
and microRNA (B) expression was
quantiﬁed (n=4 in triplicate). (C)
Myoblasts were transfected with
miR-181a or negative control, then
CAGA-12 ﬁreﬂy and Renilla Luciferase
plasmids. Following 6 h treatment with
transforming growth factor-β (TGF-β)
(2.5 ng/mL), relative luciferase activity
was quantiﬁed (n=3 in triplicate). Data
are normalised to their contemporary
control. Data presented as mean and
error bars represent SD; *p≤0.05,
t test.
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not possible to control their nutritional intake prior to
surgery. By contrast, 6/20 of the patients were fed at the time
of biopsy (two parenterally, four nasogastrically). Prior to
enrolment in the study, 18/ 20 patients were fed continuously
nasogastrically and two parenterally (because of sustained
poor enteral absorption). Nutrition targets were determined
by a preadmission weight-based formula at 20–25 kcal/kg/day.
Feed prescription was by an ICU dietician and the patients
received on average 23–25 kcal/kg/day and 1.1–1.2 g protein/
kg/day. Theoretically, the metabolic status of the muscle and
the balance between catabolic and anabolic signalling may
differ in those who were fed and those who were not. We,
therefore, reanalysed our data excluding the fed patients. No
changes in the patterns of mRNA or microRNA expression
described were seen—except with respect to MuRF-1. When
fed patients are removed from the patient cohort, the eleva-
tion in MuRF-1 expression became statistically signiﬁcant
(median MuRF-1 mRNA in starved patients 1.5 (1.1–2.3)
times higher than controls, p=0.011). Starvation is thought to
increase catabolic drive, and it may be that MuRF-1 expres-
sion is particularly sensitive to this. Feeding effects cannot
explain our in vitro observations, but it may be that GDF-15
causes muscle wasting through both direct effects on muscle
and via an interaction with nutrition.
In summary, our data conﬁrm that both circulating and
muscle expression of GDF-15 are increased in patients with
ICUAW and demonstrate an in vitro role for GDF-15 in muscle
atrophy and in microRNA suppression. Increased GDF-15 was
associated with reduced expression of muscle microRNAs, and
our data raise the possibility that by doing so sensitivity to
TGF-β signalling is increased. Future therapeutic options that
should be explored include antibodies against GDF-15 and
microRNA mimics. To date, neither of these have been trialled
in humans; however, both approaches have been successfully
demonstrated in murine models and one human anti-GDF-15
antibody is presently in development.
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